Text Box:

NEWS RELEASE                              For Information:

FOR IMMEDIATE RELEASE        Cari Reisinger

                                                            (209) 736-6769

 

 

FDA: Consumer Watchdog or Big Pharma Puppet?

Agency jobs funded directly by pharmaceutical companies

 

LOS ANGELES, CA – With more Merck secrets exposed and the Food and Drug Administration (FDA) caught endangering the American public with its weak regulatory practices, medical community heavy-hitters are calling for immediate reform.

The timely documentary Money Talks: Profits Before Patient Safety (now available on DVD) exposes how the drug industry's financial ties to the FDA compromises healthcare. Featured interviewees include Harvard’s Dr. John Abramson, author of Overdo$ed America, Columbia University’s Dr. Bob Goodman, founder of the ‘No Free Lunch’ program and Dr. Jerome Hoffman of UCLA Medical School.

“More than half of the budget of the division of the FDA that approves new drugs and oversees drug safety is being funded by the drug companies,” said Dr. John Abramson. “The watchdogs are largely drugged.”

“Right now, our government is not terribly interested in making any reforms that would be useful, because they’re so beholden to drug companies,” said Dr. Jerome Hoffman.  “We have to have the clout, influence and the organization to make it so that they can’t blithely go along making the FDA be something that has been widely and famously called a servant of the drug industry.  We have to make the FDA a servant to us.”

Filmmaker Kathleen Slattery-Moschkau said, “I think the most shocking information to come out of this documentary was the direct level of financial dependence the FDA has on the pharmaceutical industry.”

“Agency jobs and funding are sustained by the monetary success of new or existing drugs,” she said.   “This conflict of interest significantly jeopardizes public safety.”

Money Talks: Profits Before Patient Safety is filmmaker Kathleen Slattery-Moschkau’s second film about issues involving the pharmaceutical industry. Her debut feature, Side Effects, was a fictional treatment of her decade working as a sales rep for two of the nation’s top drug companies.

For more information on the important issues raised in Money Talks, visit www.moneytalksthemovie.com.  To arrange an interview with filmmaker Kathleen Slattery-Moschkau, contact Cari Reisinger of Hummingbird Pictures at (209) 736-6769 or cari@hummingbirddistribution.com.

 

###